Cargando…

Imatinib-induced podocytopathies in a patient with gastrointestinal stromal tumor

Detalles Bibliográficos
Autores principales:	Wang, Gang, Zhuo, Ning, Luo, Ying, Li, Jie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2021
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8168744/ https://www.ncbi.nlm.nih.gov/pubmed/34039238 http://dx.doi.org/10.1080/0886022X.2021.1930049

Ejemplares similares

Genome-scale CRISPR-Cas9 knockout screening in gastrointestinal stromal tumor with Imatinib resistance
por: Cao, Jie, et al.
Publicado: (2018)

GASTROINTESTINAL STROMAL TUMOR OF THE RECTUM TREATED WITH NEOADJUVANT IMATINIB FOLLOWED BY TRANSANAL ENDOSCOPIC MICROSURGERY
por: NAHAS, Caio Sergio Rizkallah, et al.
Publicado: (2015)

Two different KIT mutations may lead to different responses to imatinib in metastatic gastrointestinal stromal tumor
por: Yim, Eunjung, et al.
Publicado: (2018)

Downstaging of a Rectal Gastrointestinal Stromal Tumor by Neoadjuvant Imatinib Therapy Allowing for a Conservative Surgical Approach
por: dos Santos Fernandes, Gustavo, et al.
Publicado: (2009)

Pazopanib use preceding curative surgery in low rectal gastrointestinal stromal tumors after imatinib failure: A case report
por: Pande, Nikhil, et al.
Publicado: (2019)

Imatinib-induced Ototoxicity in a Patient with Gastrointestinal Stromal Tumor (GIST)
por: Wasif, Komal, et al.
Publicado: (2016)

Unresectable gastrointestinal stromal tumors
por: Menon, Prema, et al.
Publicado: (2011)

Podocytopathy
por: Agarwal, Sanjay K.
Publicado: (2016)

Reversible sarcopenia in patients with gastrointestinal stromal tumor treated with imatinib
por: Moryoussef, Frédérick, et al.
Publicado: (2015)

Treatment of gastrointestinal stromal tumor: focus on imatinib mesylate
por: Din, Omar S, et al.
Publicado: (2008)

Optimizing Adherence to Adjuvant Imatinib in Gastrointestinal Stromal Tumor
por: Tetzlaff, Eric D., et al.
Publicado: (2013)

Update on imatinib for gastrointestinal stromal tumors: duration of treatment
por: Linch, Mark, et al.
Publicado: (2013)

Overcoming heterogenity in imatinib-resistant gastrointestinal stromal tumor
por: Serrano, César, et al.
Publicado: (2019)

Impact of Rechallenge with Imatinib in Patients with Advanced Gastrointestinal Stromal Tumor after Failure of Imatinib and Sunitinib
por: Sawaki, Akira, et al.
Publicado: (2014)

Imatinib rechallenge in patients with advanced gastrointestinal stromal tumors following progression with imatinib, sunitinib and regorafenib
por: Vincenzi, Bruno, et al.
Publicado: (2018)

Identification of Novel Imatinib-Resistant Genes in Gastrointestinal Stromal Tumors
por: Cao, Lei, et al.
Publicado: (2022)

Heterogeneity of Metabolic Vulnerability in Imatinib-Resistant Gastrointestinal Stromal Tumor
por: Huang, Wen-Kuan, et al.
Publicado: (2020)

Imatinib induced severe skin reactions and neutropenia in a patient with gastrointestinal stromal tumor
por: Hwang, Jun-Eul, et al.
Publicado: (2010)

Imatinib-induced hepatitis treated by corticosteroids in a patient with metastatic gastrointestinal stromal tumor
por: Kang, Min Kyu, et al.
Publicado: (2019)

Imatinib-Induced Psoriasis
por: Atalay, Figen, et al.
Publicado: (2013)

Imatinib-induced Gynecomastia
por: Gupta, Pragya, et al.
Publicado: (2019)

Gastrointestinal Stromal Tumor With Chondrosarcomatous Dedifferentiation Following Imatinib Therapy
por: Koufopoulos, Nektarios, et al.
Publicado: (2021)

A narrative review of imatinib-resistant gastrointestinal stromal tumors
por: Hayashi, Yujiro, et al.
Publicado: (2021)

Update on the treatment of gastrointestinal stromal tumors (GISTs): role of imatinib
por: Quek, Richard, et al.
Publicado: (2010)

ZNF-Mediated Resistance to Imatinib Mesylate in Gastrointestinal Stromal Tumor
por: Rink, Lori, et al.
Publicado: (2013)

Optimizing Surgical and Imatinib Therapy for the Treatment of Gastrointestinal Stromal Tumors
por: Sicklick, Jason K., et al.
Publicado: (2013)

Genomic and transcriptomic analysis of imatinib resistance in gastrointestinal stromal tumors
por: Takahashi, Tsuyoshi, et al.
Publicado: (2017)

Recent Advancements in the Treatment of Rectal Gastrointestinal Stromal Tumor: In Era of Imatinib
por: Qu, Hui, et al.
Publicado: (2022)

Primary Podocytopathies After COVID-19 Vaccination
por: Timmermans, Sjoerd A.M.E.G., et al.
Publicado: (2021)

Evaluation of high-risk clinicopathological indicators in gastrointestinal stromal tumors for prognosis and imatinib treatment outcome
por: Zhao, Wen-Yi, et al.
Publicado: (2014)

Imatinib use for gastrointestinal stromal tumors among older patients in Japan and Taiwan
por: Ichinose, Yuichi, et al.
Publicado: (2022)

Advances in the research of the mechanism of secondary resistance to imatinib in gastrointestinal stromal tumors
por: Hu, Xiangchen, et al.
Publicado: (2022)

Gastric gastrointestinal stromal tumor and neuroendocrine pancreatic tumor: Always neurofibromatosis?
por: Ramos, Lídia Roque, et al.
Publicado: (2014)

Imatinib Plasma Monitoring-Guided Dose Modification for Managing Imatinib-Related Toxicities in Gastrointestinal Stromal Tumor Patients
por: Yoon, Shinkyo, et al.
Publicado: (2013)

Neoadjuvant versus adjuvant imatinib in primary localized gastrointestinal stromal tumor
por: Ling, Jiayu, et al.
Publicado: (2023)

Eyebrow Whitening Induced by Imatinib
por: Yavasoglu, Irfan, et al.
Publicado: (2020)

Hepatitis B Virus Reactivation in Gastrointestinal Stromal Tumor Patients Treated With Imatinib
por: Lei, Tianxiang, et al.
Publicado: (2021)

Risk factors for gastrointestinal stromal tumor recurrence in patients treated with adjuvant imatinib
por: Joensuu, Heikki, et al.
Publicado: (2014)

Role of surgery in patients with focally progressive gastrointestinal stromal tumors resistant to imatinib
por: Gao, Xiaodong, et al.
Publicado: (2016)

Preoperative imatinib for patients with primary unresectable or metastatic/recurrent gastrointestinal stromal tumor
por: Shen, Chaoyong, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_6j63au95jf1oiq4tal3v8ifo7t